Please use this identifier to cite or link to this item:
Title: Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
Austin Authors: Ding, NS;Hart, A;De Cruz, Peter
Affiliation: Department of Gastroenterology, St Mark's Hospital, Harrow, UK
Department of Medicine, Imperial College London, London, UK
Department of Medicine, The University of Melbourne, Victoria, Australia
Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Jan-2016 2015-10-30
Publication information: Alimentary Pharmacology and Therapeutics 2016; 43(1): 30-51
Abstract: BACKGROUND: Nonresponse and loss of response to anti-TNF therapies in Crohn's disease represent significant clinical problems for which clear management guidelines are lacking. AIM: To review the incidence, mechanisms and predictors of primary nonresponse and secondary loss of response to formulate practical clinical algorithms to guide management. METHODS: Through a systematic literature review, 503 articles were identified which fit the inclusion criteria. RESULTS: Primary nonresponse to anti-TNF treatment affects 13-40% of patients. Secondary loss of response to anti-TNF occurs in 23-46% of patients when determined according to dose intensification, and 5-13% of patients when gauged by drug discontinuation rates. Recent evidence suggests that the mechanisms underlying primary nonresponse and secondary loss of response are multifactorial and include disease characteristics (phenotype, location, severity); drug (pharmacokinetic, pharmacodynamic or immunogenicity) and treatment strategy (dosing regimen) related factors. Clinical algorithms that employ therapeutic drug monitoring (using anti-TNF tough levels and anti-drug antibody levels) may be used to determine the underlying cause of primary nonresponse and secondary loss of response respectively and guide clinicians as to which patients are most likely to respond to anti-TNF therapy and help optimise drug therapy for those who are losing response to anti-TNF therapy. CONCLUSIONS: Nonresponse or loss of response to anti-TNF occurs commonly in Crohn's disease. Clinical algorithms utilising therapeutic drug monitoring may establish the mechanisms for treatment failure and help guide the subsequent therapeutic approach.
DOI: 10.1111/apt.13445
PubMed URL:
Type: Journal Article
Subjects: Algorithms
Antibodies, Monoclonal
Crohn Disease
Tumor Necrosis Factor-alpha
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.